Previous studies have demonstrated that the CXCL12/CXCR4 signaling axis plays a critical role in the pathogenesis of SLE, suggesting that targeting this pathway may offer a novel therapeutic strategy for improving SLE outcomes (Chong and Mohan, 2009). Here, CXCL12 is linked to systemic lupus erythematosus.